Briota's SURAKSHA platform utilizes Point of Care Testing (POCT) technology to provide immediate and reliable diagnostic results for twelve non-communicable diseases, including asthma, diabetes, and various cancers. This enables healthcare providers to deliver timely diagnoses and treatment plans, ultimately improving patient outcomes and reducing healthcare costs.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Non-communicable diseases (NCDs) such as asthma, diabetes, and cancer pose a significant global health burden, particularly in regions with limited access to healthcare facilities. Delayed or inaccessible diagnostic testing hinders timely diagnoses and treatment plans, leading to poorer patient outcomes and increased healthcare costs.
Solution
Briota's SURAKSHA platform is a point-of-care testing (POCT) solution designed to enhance diagnostic capabilities for physicians and clinics, especially in primary and community care settings. The platform enables immediate and reliable diagnostic results for twelve NCDs, empowering healthcare providers to deliver timely and accurate diagnoses. By providing on-the-spot testing, SURAKSHA facilitates quicker and more effective treatment plans, fostering trust between patients and healthcare providers while contributing to improved health outcomes and reduced healthcare costs. The system integrates with existing continuum of care models, including eSanjivani and Tele-MANAS, for comprehensive patient management.
Target Audience
The primary target audience includes physicians, clinics, and community health centers in areas with limited access to diagnostic facilities, as well as government healthcare programs focused on NCD screening and management.
Features
- Portable POCT backpack for on-site NCD screening.
- AI-powered application for NCD assessment.
- Comprehensive packages for both men (10 NCDs) and women (12 NCDs).
- Specialized disease coverage for Tuberculosis, Epilepsy, Sickle Cell Anemia, and Lung Cancer.
- Integration with government telehealth initiatives like eSanjivani and Tele-MANAS.